Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Functional Clear all
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function and Cognition in CKD

NCT03689569
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Resistant starch, Exercise, Starch
Dietary Supplement · Behavioral
Lead sponsor
Springfield College
Other
Eligibility
30 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Effect of Low Frequency Ultrasound on Kidney Function

NCT02026544
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Low Frequency Therapeutic Ultrasound
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614
View directory record Official record
Conditions
Renal Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Rialto, California • Yucaipa, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 8:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 8:45 AM EDT
Recruiting Phase 4 Interventional

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

NCT06140537
View directory record Official record
Conditions
Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

NCT04750577
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Placebo matching BI 685509, BI 685509
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Victorville, California • Waterbury, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 25, 2026, 8:45 AM EDT
Completed No phase listed Observational

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

NCT04487301
View directory record Official record
Conditions
Peripheral Artery Disease, End Stage Renal Disease on Dialysis
Interventions
Not listed
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

NCT02002767
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Velpatasvir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 25, 2026, 8:45 AM EDT
Not listed Phase 2 Interventional

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplant
Interventions
Belatacept, Calcineurin Inhibitor
Drug
Lead sponsor
Nair, Vinay, D.O.
Individual
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 25, 2026, 8:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function

NCT04334135
View directory record Official record
Conditions
Racial Disparities, Blood Pressure, Cardiovascular Risk Factor, Renal Function
Interventions
MitoQ
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
19 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Physical Activity Program for Older Renal Transplant Candidates

NCT00857974
View directory record Official record
Conditions
Renal Transplant Candidate
Interventions
Physical Activity
Other
Lead sponsor
Wake Forest University
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy

NCT00842023
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Nesiritide, Nitroglycerin
Drug
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Inglewood, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated No phase listed Observational

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

NCT02730715
View directory record Official record
Conditions
KIDNEY TRANSPLANTATION
Interventions
Basiliximab, Thymoglobulin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Early Phase 1 Interventional

Belatacept for Renal Transplant Recipients With Delayed Graft Function

NCT02134288
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Belatacept, Everolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

NCT00003342
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

NCT01331941
View directory record Official record
Conditions
Advanced Solid Tumors, Kidney Disease, Renal Impairment
Interventions
AMG 386 + Paclitaxel, AMG 386
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151
View directory record Official record
Conditions
Overweight or Obesity, CKD, Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

NCT01825889
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Evacetrapib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614
View directory record Official record
Conditions
Heart Failure, Congestive, Renal Insufficiency
Interventions
KW-3902IV
Drug
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 25, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies

NCT03387514
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 25, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Direct Renin Inhibition and the Kidney

NCT01217736
View directory record Official record
Conditions
Renal Function
Interventions
aliskiren, placebo, VTP-27999
Drug
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 25, 2026, 8:45 AM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 25, 2026, 8:45 AM EDT
Recruiting Phase 3 Interventional

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

NCT06217302
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 25, 2026, 8:45 AM EDT